1.Coskun T., Sloop KW., Loghin C., Alsina-Fernandez J., Urva S., Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018. 18:3–14.
Article
2.Rosenstock J., Wysham C., Frías JP., Kaneko S., Lee CJ., Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021. 398:143–55. Erratum in: Lancet 2021;398):212.
Article
3.Frías JP., Davies MJ., Rosenstock J., Pérez Manghi FC., Fernández Landó L., Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021. 385:503–15.
Article
4.Ludvik B., Giorgino F., Jódar E., Frias JP., Fernández Landó L., Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021. 398:583–98.
Article
5.Del Prato S., Kahn SE., Pavo I., Weerakkody GJ., Yang Z., Doupis J., SURPASS-4 Investigators, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021. 398:1811–24.
6.Dahl D., Onishi Y., Norwood P., Huh R., Bray R., Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022. 327:534–45.
Article
7.Inagaki N., Takeuchi M., Oura T., Imaoka T., Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022. 10:623–33.
Article
8.Kadowaki T., Chin R., Ozeki A., Imaoka T., Ogawa Y. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022. 10:634–44.
9.Sattar N., McGuire DK., Pavo I., Weerakkody GJ., Nishiyama H., Wiese RJ, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022. 28:591–8.
10.Heerspink HJL., Sattar N., Pavo I., Haupt A., Duffin KL., Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022. 10:774–85.